Hydromorphone in the management of cancer-related pain: an update on routes of administration and dosage forms.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Pharmacy & Pharmaceutical Sciences

• Publication date

  2007-10-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.18433/J3VC75PMID 18261371
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Providing Constant Analgesia with OROS® Hydromorphone

  2007cited by this paper
• Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials.

  2006cited by this paper
• Overview of Oral Modified-Release Opioid Products for the Management of Chronic Pain

  2006cited by this paper
• Clinical spectrum of the osmotic-controlled release oral delivery system (OROS*), an advanced oral delivery form

  2006cited by this paper
• Intrathecal hydromorphone for intractable nonmalignant pain: a retrospective study.

  2006cited by this paper
• (807) : 24-hour transdermal delivery of hydromorphone hydrochloride

  2006cited by this paper
• Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials.

  2005cited by this paper
• Clinical Pharmacology and Pharmacokinetics of Once‐Daily Hydromorphone Hydrochloride Extended‐Release Capsules

  2005cited by this paper
• The "pain pen" for breakthrough cancer pain: a promising treatment.

  2005cited by this paper
• Hydromorphone.

  2005cited by this paper
• FDA asks Purdue Pharma to withdraw Palladone.

  2005cited by this paper
• The use of opioids in the postoperative setting: focus on morphine, hydromorphone, and fentanyl.

  2005cited by this paper
• Palladone for chronic pain.

  2005cited by this paper
• A Multiple-Dose Phase I Study of Intranasal Hydromorphone Hydrochloride in Healthy Volunteers

  2004cited by this paper
• Massive hydromorphone dose delivered subcutaneously instead of intrathecally: guidelines for prevention and management of opioid, local anesthetic, and clonidine overdose.

  2004cited by this paper
• Effect of Fluticasone Propionate Nasal Spray on Bioavailability of Intranasal Hydromorphone Hydrochloride in Patients with Allergic Rhinitis

  2004cited by this paper
• A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002.

  2004cited by this paper
• Continuous intrathecal infusion of hydromorphone: safety in the sheep model and clinical implications.

  2004cited by this paper
• Pharmacokinetic and pharmacodynamic evaluation of intravenous hydromorphone in cats.

  2004cited by this paper
• In vivo pain relief effectiveness of an analgesic-anesthetic carrying biodegradable controlled release rod systems

  2003cited by this paper
• Pharmacokinetics and Bioavailability of Single-Dose Intranasal Hydromorphone Hydrochloride in Healthy Volunteers

  2003cited by this paper
• A systematic review of hydromorphone in acute and chronic pain.

  2003cited by this paper
• Morphine and hydromorphone for postoperative analgesia: focus on safety.

  2003cited by this paper
• Opioid prescription for terminally ill outpatients in a district of northern Italy: a retrospective survey.

  2003cited by this paper
• Antinociceptive effects of hydromorphone, bupivacaine and biphalin released from PLGA polymer after intrathecal implantation in rats.

  2003cited by this paper
• Handbook of Pharmaceutical Controlled release Technology

  2002cited by this paper
• Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.

  2002cited by this paper
• National All Schedules Prescription Electronic Reporting Act (NASPER): balancing substance abuse and medical necessity.

  2002cited by this paper
• Supportive therapy of elderly cancer patients.

  2002cited by this paper
• Epidural and intrathecal analgesia for cancer pain.

  2002cited by this paper
• Input Characteristics and Bioavailability after Administration of Immediate and a New Extended-release Formulation of Hydromorphone in Healthy Volunteers

  2002cited by this paper
• Clinical Pharmacology of Opioids for Pain

  2002cited by this paper
• Intrathecal hydromorphone for chronic nonmalignant pain: a retrospective study.

  2001cited by this paper
• Opioid formulations: tailoring to the needs in chronic pain

  2001cited by this paper
• Analgesia in the Intensive Care Unit

  2001cited by this paper
• Hydromorphone: pharmacology and clinical applications in cancer patients

  2001cited by this paper
• Pharmacodynamics of Orally Administered Sustained- release Hydromorphone in Humans

  2001cited by this paper
• Hydromorphone: a cost-effective alternative to the use of oxymorphone.

  2000cited by this paper
• Future directions in the management of pain by intraspinal drug delivery.

  2000cited by this paper
• Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers

  2000cited by this paper
• Trends in medical use and abuse of opioid analgesics.

  2000cited by this paper
• Neuroexcitatory Effects Of Morphine And Hydromorphone: Evidence Implicating The 3‐Glucuronide Metabolites

  2000cited by this paper
• Comparison of epidural morphine, hydromorphone and fentanyl for postoperative pain control in children undergoing orthopaedic surgery

  1999cited by this paper
• Alternatives to oral opioids for cancer pain.

  1999cited by this paper
• Continuous subcutaneous infusion of morphine vs. hydromorphone: a controlled trial.

  1999cited by this paper
• Novel routes of opioid administration.

  1998cited by this paper
• Comparative efficacy of patient‐controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation

  1997cited by this paper
• New approaches to pain control in patients with cancer.

  1997cited by this paper
• Hydromorphone polymer implant. A potential alternative to methadone maintenance.

  1997cited by this paper
• Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study

  1997cited by this paper
• Comparative clinical efficacy and safety of a novel controlled‐release oxycodone formulation and controlled‐release hydromorphone in the treatment of cancer pain

  1997cited by this paper
• Hydromorphone analgesia after intravenous bolus administration

  1997cited by this paper
• Antinociceptive and immunosuppressive effects of opiate drugs: a structure‐related activity study

  1997cited by this paper
• A Multidimensional Comparison of Morphine and Hydromorphone Patient-Controlled Analgesia

  1996cited by this paper
• Epidural morphine vs hydromorphone in post-Caesarean section patients

  1996cited by this paper
• Opioid rotation in patients with cancer pain: A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine

  1996cited by this paper
• Morphine in cancer pain: modes of administration. Expert Working Group of the European Association for Palliative Care.

  1996cited by this paper
• A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group.

  1996cited by this paper
• Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone.

  1996cited by this paper
• In vitro and in vivo studies of subcutaneous hydromorphone implants designed for the treatment of cancer pain

  1996cited by this paper
• Clinical analgesic equivalence for morphine and hydromorphone with prolonged PCA

  1996cited by this paper
• Fortnightly Review: Morphine in cancer pain: modes of administration

  1996cited by this paper
• High-tech pain management utilizing multiple analgesics—a case study

  1995cited by this paper
• Opioid pharmacotherapy in the management of cancer pain. A survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration

  1995cited by this paper
• Steady‐State Pharmacokinetics of Hydromorphone and Hydromorphone‐3‐Glucuronide in Cancer Patients After Immediate and Controlled‐Release Hydromorphone

  1995cited by this paper
• The costs of managing severe cancer pain and potential savings from transdermal administration.

  1994cited by this paper
• Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain

  1994cited by this paper
• Morphine and hydromorphone epidural analgesia. A prospective, randomized comparison.

  1992cited by this paper
• Subcutaneous narcotic infusions for cancer pain: treatment outcome and guidelines for use.

  1992cited by this paper
• Continuous subcutaneous infusions for pain control.

  1991cited by this paper
• Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain.

  1991cited by this paper
• Continuous subcutaneous infusions for pain control.

  1991cited by this paper
• In vitro and in vivo evaluation of transdermal iontophoretic delivery of hydromorphone

  1990cited by this paper
• Subcutaneous infusions for control of cancer symptoms.

  1990cited by this paper
• Clinical analgesic assay of repeated and single doses of heroin and hydromorphone

  1990cited by this paper
• Use of the subcutaneous route for the administration of narcotics in patients with cancer pain

  1988cited by this paper
• Pharmacokinetics and Bioavailability of Hydromorphone: Effect of Various Routes of Administration

  1988cited by this paper
• Opioid analgesics in cancer pain: current practice and controversies.

  1988cited by this paper
• Opioid analgesics in cancer pain: current practice and controversies.

  1988cited by this paper
• Continuous sc infusion of narcotics using a portable disposable device in patients with advanced cancer.

  1987cited by this paper
• Absolute Bioavailability of Hydromorphone After Peroral and Rectal Administration in Humans: Saliva/Plasma Ratio and Clinical Effects

  1987cited by this paper
• Epidural hydromorphone: a double-blind comparison with intramuscular hydromorphone for postcesarean section analgesia.

  1987cited by this paper
• I.v. infusion of opioids for cancer pain: clinical review and guidelines for use.

  1986cited by this paper
• Epidural Hydromorphone for Postcesarean Analgesia

  1985cited by this paper
• Pharmacokinetics and Bioavailability of Hydromorphone Following Intravenous and Oral Administration to Human Subjects

  1981cited by this paper
• Dental evaluation of hydromorphone (Dilaudid) for oral and maxillo-facial surgery.

  1969cited by this paper
• Dental evaluation of hydromorphone (Dilaudid) for oral and maxillo-facial surgery.

  1969cited by this paper
• Postoperative Analgesia with Hydromorphone and Meperidine: A Double‐Blind Comparison

  1968cited by this paper

• A General Picture of Cucurbit[8]uril Host-Guest Binding

  2021cites this paper
• Fluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity

  2021cites this paper
• Radiopharmaceutical Sciences

  2020cites this paper
• Systémová terapie bolesti z pohledu moderních lékových forem

  2020cites this paper
• Prescription opioid induce gut dysbiosis and exacerbate colitis in a murine model of Inflammatory Bowel Disease.

  2019cites this paper
• Cancer Pain Management: Opioid Analgesics, Part 2

  2017cites this paper
• Novel Positron-Emitting Radiopharmaceuticals

  2017cites this paper
• An exploration into the level and characteristics of pain experienced by women treated for cervical cancer at an academic hospital in Johannesburg

  2016cites this paper
• Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study

  2016cites this paper
• Fluorinated steroids and their derivatives

  2016cites this paper
• Emerging Radiopharmaceuticals in Clinical Oncology

  2016cites this paper
• Integrating Good Pain-Management and Assessment Practices into Everyday Patient Care and Situations

  2014cites this paper
• Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta-[18F]fluoro-5alpha-dihydrotestosterone (FDHT) as radiopharmaceuticals.

  2014cites this paper
• Opioids in treatment of cancer pain

  2014cites this paper
• Alternative synthesis for the preparation of 16α-[(18) F]fluoroestradiol.

  2013cites this paper
• Radiopharmaceuticals for Imaging in Oncology with Special Emphasis on Positron-Emitting Agents

  2013cites this paper
• Non-peptidyl (18)F-labelled PET tracers as radioindicators for the noninvasive detection of cancer.

  2013cites this paper
• PRINCIPLES OF PAIN MANAGEMENT

  2012cites this paper
• Intrathecal hydromorphone added to hyperbaric bupivacaine for postoperative pain relief after knee arthroscopic surgery: a prospective, randomised, controlled trial

  2012cites this paper
• Alternative opioids and administration routes

  2012cites this paper
• Analgesics for Cancer Pain

  2012cites this paper
• Efficacy of opioid rotation to continuous parenteral hydromorphone in advanced cancer patients failing on other opioids

  2011cites this paper
• Novel Use of Hydromorphone as a Pretreatment Agent: A Double-blind, Randomized, Controlled Study in Adult Korean Surgical Patients.

  2011cites this paper
• Drugs of anaesthesia and cancer.

  2010cites this paper
• The Role of OROS® Hydromorphone in the Management of Cancer Pain

  2010cites this paper
• REVIEW ARTICLE The Role of OROS ® Hydromorphone in the Management of Cancer Pain

  2010cites this paper
• OROS® Hydromorphone Prolonged Release

  2010cites this paper
• Imaging response to systemic therapy for bone metastases

  2009cites this paper
• Transdermal Iontophoresis of Hydromorphone across Hairless Rat Skin In Vitro

  2009cites this paper
• Current world literature. Pain: cancer.

  2009cites this paper
• Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.

  2008cites this paper
• Synthese von 11C‐, 18F‐, 15O‐ und 13N‐Radiotracern für die Positronenemissionstomographie

  2008cites this paper
• Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography.

  2008cites this paper